First report of in vitro selection of RNA aptamers targeted to recombinant Loxosceles laeta spider toxins

BACKGROUND: Loxoscelism is the envenomation caused by the bite of Loxosceles spp. spiders. It entails severe necrotizing skin lesions, sometimes accompanied by systemic reactions and even death. There are no diagnostic means and treatment is mostly palliative. The main toxin, found in several isofor...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Sapag,Amalia, Salinas-Luypaert,Catalina, Constenla-Muñoz,Carlos
Lenguaje:English
Publicado: Sociedad de Biología de Chile 2014
Materias:
Acceso en línea:http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0716-97602014000100002
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:scielo:S0716-97602014000100002
record_format dspace
spelling oai:scielo:S0716-976020140001000022015-10-30First report of in vitro selection of RNA aptamers targeted to recombinant Loxosceles laeta spider toxinsSapag,AmaliaSalinas-Luypaert,CatalinaConstenla-Muñoz,Carlos Antivenom Loxosceles laeta RNA aptamers SELEX SMD-Ll1 SMD-Ll2 Sphingomyelinase D BACKGROUND: Loxoscelism is the envenomation caused by the bite of Loxosceles spp. spiders. It entails severe necrotizing skin lesions, sometimes accompanied by systemic reactions and even death. There are no diagnostic means and treatment is mostly palliative. The main toxin, found in several isoforms in the venom, is sphingomyelinase D (SMD), a phospholipase that has been used to generate antibodies intended for medical applications. Nucleic acid aptamers are a promising alternative to antibodies. Aptamers may be isolated from a combinatorial mixture of oligonucleotides by iterative selection of those that bind to the target. In this work, two Loxosceles laeta SMD isoforms, Ll1 and Ll2, were produced in bacteria and used as targets with the aim of identifying RNA aptamers that inhibit sphingomyelinase activity. RESULTS: Six RNA aptamers capable of eliciting partial but statistically significant inhibitions of the sphingomyelinase activity of recombinant SMD-Ll1 and SMD-Ll2 were obtained: four aptamers exert ~17% inhibition of SMD-Ll1, while two aptamers result in ~25% inhibition of SMD-Ll2 and ~18% cross inhibition of SMD-Ll1. CONCLUSIONS: This work is the first attempt to obtain aptamers with therapeutic and diagnostic potential for loxoscelism and provides an initial platform to undertake the development of novel anti Loxoscelesvenom agents.info:eu-repo/semantics/openAccessSociedad de Biología de ChileBiological Research v.47 20142014-01-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0716-97602014000100002en10.1186/0717-6287-47-2
institution Scielo Chile
collection Scielo Chile
language English
topic Antivenom
Loxosceles laeta
RNA aptamers
SELEX
SMD-Ll1
SMD-Ll2
Sphingomyelinase D
spellingShingle Antivenom
Loxosceles laeta
RNA aptamers
SELEX
SMD-Ll1
SMD-Ll2
Sphingomyelinase D
Sapag,Amalia
Salinas-Luypaert,Catalina
Constenla-Muñoz,Carlos
First report of in vitro selection of RNA aptamers targeted to recombinant Loxosceles laeta spider toxins
description BACKGROUND: Loxoscelism is the envenomation caused by the bite of Loxosceles spp. spiders. It entails severe necrotizing skin lesions, sometimes accompanied by systemic reactions and even death. There are no diagnostic means and treatment is mostly palliative. The main toxin, found in several isoforms in the venom, is sphingomyelinase D (SMD), a phospholipase that has been used to generate antibodies intended for medical applications. Nucleic acid aptamers are a promising alternative to antibodies. Aptamers may be isolated from a combinatorial mixture of oligonucleotides by iterative selection of those that bind to the target. In this work, two Loxosceles laeta SMD isoforms, Ll1 and Ll2, were produced in bacteria and used as targets with the aim of identifying RNA aptamers that inhibit sphingomyelinase activity. RESULTS: Six RNA aptamers capable of eliciting partial but statistically significant inhibitions of the sphingomyelinase activity of recombinant SMD-Ll1 and SMD-Ll2 were obtained: four aptamers exert ~17% inhibition of SMD-Ll1, while two aptamers result in ~25% inhibition of SMD-Ll2 and ~18% cross inhibition of SMD-Ll1. CONCLUSIONS: This work is the first attempt to obtain aptamers with therapeutic and diagnostic potential for loxoscelism and provides an initial platform to undertake the development of novel anti Loxoscelesvenom agents.
author Sapag,Amalia
Salinas-Luypaert,Catalina
Constenla-Muñoz,Carlos
author_facet Sapag,Amalia
Salinas-Luypaert,Catalina
Constenla-Muñoz,Carlos
author_sort Sapag,Amalia
title First report of in vitro selection of RNA aptamers targeted to recombinant Loxosceles laeta spider toxins
title_short First report of in vitro selection of RNA aptamers targeted to recombinant Loxosceles laeta spider toxins
title_full First report of in vitro selection of RNA aptamers targeted to recombinant Loxosceles laeta spider toxins
title_fullStr First report of in vitro selection of RNA aptamers targeted to recombinant Loxosceles laeta spider toxins
title_full_unstemmed First report of in vitro selection of RNA aptamers targeted to recombinant Loxosceles laeta spider toxins
title_sort first report of in vitro selection of rna aptamers targeted to recombinant loxosceles laeta spider toxins
publisher Sociedad de Biología de Chile
publishDate 2014
url http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0716-97602014000100002
work_keys_str_mv AT sapagamalia firstreportofinvitroselectionofrnaaptamerstargetedtorecombinantloxosceleslaetaspidertoxins
AT salinasluypaertcatalina firstreportofinvitroselectionofrnaaptamerstargetedtorecombinantloxosceleslaetaspidertoxins
AT constenlamunozcarlos firstreportofinvitroselectionofrnaaptamerstargetedtorecombinantloxosceleslaetaspidertoxins
_version_ 1718441509774163968